An Open-Labeled Pilot Study of Biomarker Response in Patients With Colorectal Cancer or Endoscopically Non-Resectable Adenomas Following Short-Term Exposure to Metformin Extended Release (ER)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Metformin (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 18 Nov 2015 Biomarkers information updated
- 09 May 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-1150).
- 08 May 2013 Planned end date changed from 1 Sep 2017 to 1 May 2017 as reported by ClinicalTrials.gov.